Dr. Gaffar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
10710 Charter Drive
#G020
Columbia, MD 21044Phone+1 410-964-2212Fax+1 410-964-0380- Is this information wrong?
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2002 - 2005
Rutgers Health/Robert Wood Johnson Medical SchoolChief Residency, Internal Medicine, 2001 - 2002- Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1998 - 2001
Saba University School of MedicineClass of 1998
Certifications & Licensure
MO State Medical License 2020 - 2026
FL State Medical License 2002 - 2026
MD State Medical License 2005 - 2024
PA State Medical License 2006 - 2012
NJ State Medical License 2001 - 2005- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Castle Connolly Top Doctor Castle Connolly, 2022-2024
- Top Doctor Baltimore Magazine, 2017-2019
Clinical Trials
- IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2013 Apr 29
- A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer Start of enrollment: 2020 Dec 31
Publications & Presentations
PubMed
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett ...> ;The New England journal of medicine.
- 362 citationsNeratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3..., , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;The Lancet. Oncology. 2017 Dec 1
- 117 citationsCommunity-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma RegimensRuben Niesvizky, Ian W. Flinn, Robert M. Rifkin, Nashat Y. Gabrail, Veena Charu, Billy Clowney, James Essell, Yousuf Gaffar, Thomas A. Warr, Rachel Neuwirth, Yanyan Zh...> ;Journal of Clinical Oncology. 2015 Jun 8
- Join now to see all
Committees
- Member, US Oncology GI Oncology Research Committee 2020 - Present
- Member, US Oncology Thoracic Oncology Committee 2020 - Present
Professional Memberships
- Member
Other Languages
- Spanish
Hospital Affiliations
Johns Hopkins Howard County Medical CenterColumbia, Maryland
External Links
- Biohttps://marylandoncology.com/staff/yousuf-a-gaffar-m-d-2/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
